Anti-PD1 in combination with an inhibitor of PCSK9 to increase MHC class I molecule expression on tumor cells as immunotherapy for NSCLC

Administered By

Medicine, Medical Oncology

Awarded By

Department of Defense

Contributors

Antonia, Scott Joseph Principal Investigator
Kelley, Michael John Co Investigator
Nixon, Andrew Benjamin Co Investigator
Owzar, Kouros Director
Shi, Pixu Biostatistician
Wang, Xiaofei Biostatistician
Weinhold, Kent James Laboratory Director

Start/End

June 15, 2021 - June 14, 2024